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Notch signaling is an evolutionary con-
served pathway that is mediated by cell-
cell contact. It is involved in a variety of
developmental processes and has an es-
sential role in vascular development and
angiogenesis. Delta-like 4 (Dll4) is a Notch
ligand that is up-regulated during angio-
genesis. It is expressed in endothelial
cells and regulates the differentiation be-
tween tip cells and stalk cells of neovascu-
lature. Here, we present evidence that
Dll4 is incorporated into endothelial exo-
somes. It can also be incorporated into
the exosomes of tumor cells that over-
express Dll4. These exosomes can trans-
fer the Dll4 protein to other endothelial
cells and incorporate it into their cell
membrane, which results in an inhibition
of Notch signaling and a loss of Notch
receptor. Transfer of Dll4 was also shown
in vivo from tumor cells to host endothe-
lium. Addition of Dll4 exosomes confers a
tip cell phenotype on the endothelial
cell, which results in a high Dll4/Notch-
receptor ratio, low Notch signaling, and
filopodia formation. This was further evi-
denced by increased branching in a tube-
formation assay and in vivo. This reversal
in phenotype appears to enhance vessel
formation and is a new form of signaling
for Notch ligands that expands their sig-
naling potential beyond cell-cell contact.
(Blood. 2010;116(13):2385-2394)
Introduction
Notch signaling is a cell-cell signaling pathway mediated by
membrane-tethered receptor-ligand interactions. It is highly con-
served during evolution and has a role in several biologic pro-
cesses, such as cell fate determination and differentiation.1 Re-
cently, Notch signaling has been implicated in vascular development
and angiogenesis.2 Delta-like 4 (Dll4) expression is particularly
critical for angiogenesis, because haploinsufficiency results in
vascular abnormalities and embryonic lethality.3 Its expression is
largely restricted to the endothelium of developing vessels, and it is
found at the tip cell of developing arteries, where it regulates the
number of tip cells to control vessel sprouting and branching.2
Although much is known about Notch signaling after cleavage,
the mechanism by which Delta-like ligands (DLLs) trigger this
cleavage is less understood. Recent evidence suggests that DLL
endocytosis is crucial in regulating its function, and several models
have been proposed to explain the requirement for endocytosis
(reviewed in Le Borgne4). One hypothesis suggests that endocyto-
sis of DLL allows the ligand to undergo posttranslational modifica-
tion or an association with a cofactor in the recycling endosome to
make it a more effective ligand.5 Trafficking of DLL on recycling
endosomes could also serve to cluster the protein and increase its
affinity for Notch, because clustering of a recombinant form of
DLL has been shown to be more effective at binding and activating
Notch.6 Accumulation of DLL in intracellular vesicles has been
described in Drosophila and zebrafish with localization to endo-
cytic vesicles, which correlates well with Notch signaling.7 This
has led to speculation that DLL may be incorporated into exosomes.8
Exosomes are produced in multivesicular bodies that are produced
via endocytosis. Invagination of the limiting membrane of multivesicu-
lar bodies generates intraluminal vesicles that contain endocytic and
transmembrane proteins for recycling. Multivesicular bodies can fuse
with lysosomes to degrade their cargo or fuse with the plasma
membrane to release these vesicles into the extracellular space. These
vesicles, now called exosomes, display the endocytosed transmembrane
proteins in the same orientation as at the plasma membrane.9 They can
be detected in the circulation and have roles in antigen presentation and
coagulation.10 It has been postulated that exosomes have signaling
potential11; however, there is no direct evidence that DLLis incorporated
into exosomes, although it has been noted that conditioned media from
Delta-expressing S2 cells contains soluble full-length Delta that can
activate Notch signaling.12
In this study, we investigated the possibility that Dll4 is
incorporated into exosomes. We demonstrated that human umbili-
cal vein endothelial cells (HUVECs) naturally produce exosomes
that contain Dll4. Dll4 could also be incorporated into the
exosomes of tumor cells that overexpressed Dll4. These exosomes
can transfer the Dll4 protein from one cell type to another and
incorporate it into the plasma membrane in vitro and in vivo.
Surprisingly, the Dll4-containing exosomes can inhibit Notch
signaling in vitro and appear to switch the endothelial cell
phenotype toward tip cells. This results in an increase in vessel
density in vitro and an increase in branching in vivo. These results
suggest a new aspect to DLL/Notch signaling that does not require
direct cell-cell contact.
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Methods
Cell culture and reagents
HUVECs (Lonza) were cultured in M199 media supplemented with
10% fetal calf serum (Sigma-Aldrich), 50 mg/L ECGS (endothelial cell
growth supplement; BD Biosciences), and 10 U/mL heparin (Sigma-
Aldrich). The cells between passages 3 and 7 were used. U87GM cells
(including Dll4-overexpressing cells) were cultured in Dulbecco modified
Eagle medium supplemented with 10% fetal calf serum. Production of the
U87 cell line overexpressing Dll4 has been described previously.13 Recom-
binant human Dll4 extracellular domain was purchased from R&D
Systems. It was coated onto tissue culture dishes overnight at a concentra-
tion of 1 g/mL in 0.2% gelatin. The -secretase inhibitor dibenzazepine
(Calbiochem) was dissolved in dimethyl sulfoxide and used at a concentra-
tion of 10nM.
Quantitative polymerase chain reaction protocol
RNA extraction, the quantitative polymerase chain reaction protocol, and
primers have been described previously.14
Western blotting
Proteins were separated with sodium dodecyl sulfate–polyacrylamide gel
electrophoresis by use of standard techniques. Antibodies were purchased
from the following companies: Notch1 cleaved intracellular domain
(NICD) and Dll4 from Cell Signaling; -tubulin, -actin, and green
fluorescent protein from Sigma-Aldrich; Notch1 extracellular domain,
TSG101, and mouse Dll4 from Abcam; Rab5 from Santa Cruz; and Lamp1
from BD Biosciences. Anti–human Dll4 (Regeneron 242) was a gift from
Regeneron. Secondary antibodies were purchased from DAKO.
Protein identification by mass spectrometry
Isolated U87 control and U87 Dll4 exosome material was precipitated and
desalted with chloroform/methanol.15 Samples were resuspended in buffer
that contained 6M urea and 100mM Tris pH 7.8, followed by reduction,
alkylation, and in-solution trypsin digestion as described previously.16
Trypsin digested protein material was analysed by liquid chromatography–
mass spectrometry/mass spectrometry with an UltiMate (LC Packings,
Dionex) high-performance liquid chromatography system coupled online to
a 3-dimensional high-capacity ion trap (HCTplus, Bruker Daltonics) mass
spectrometer as described previously.16
Protein identification and label-free quantitative analysis by
nano-UPLC-MSE tandem mass spectrometry
The digested material prepared above was subjected to nano-
ultraperformance liquid chromatography tandem mass spectrometry analy-
sis (nano-UPLC-MSE or nano-MS/MS) as described previously.17
NanoSight analysis of exosome size
U87 control and HUVEC exosome preparations were assessed with the
NanoSight LM10 (NanoSight, Ltd) system. Exosome preparations were
stored at 80°C, thawed at room temperature, and then diluted in
phosphate-buffered saline (PBS) that had been shown to be free of any
contaminant particles. U87 control and HUVEC exosome samples were
diluted accordingly so that approximately 1000 particles were analyzed per
sample. The culture media from both cell types were analyzed at the same
dilution, independent of the sample, and no contaminating particles were
detected. Particles in the range of 80 to 300 nm have been detected
previously in the medium of live cells by a related technique, dynamic light
scattering. Larger apoptotic vesicles are detected between 400 and 1200 nm.18
Exosome isolation and labeling
U87 cells were incubated in Opti-Mem (Gibco) for 48 hours to obtain
exosomes. At the point of harvest, the cells were stained with trypan blue to
check viability. HUVECs were cultured in endothelial cell growth medium-2
(EGM2) for 48 hours before being harvested. HUVECs were plated on
Dll4-coated plates to induce the production of Dll4 and subsequently the
production of exosomes that contained Dll4. The EGM2 had been
centrifuged previously at 110 000g for 16 hours to remove contaminating
exosomes. Exosomes were harvested from cell media by ultracentrifugation
as described previously.19 The resulting exosomes were resuspended in PBS
or lysed in radioimmunoprecipitation assay buffer. The exosomes were
labeled with the fluorescent membrane dye PKH67 (Sigma-Aldrich)
according to the manufacturer’s instructions.
Biotinylation of cell-surface proteins
U87 and HUVEC cell-surface proteins were labeled with biotin and purified
with the Pierce cell-surface protein isolation kit according to the manufac-
turer’s instructions.
Tube-formation assay
Normal dermal fibroblasts were seeded into the wells of a 24-well plate at a
density of 2  104/well. The cells were allowed to adhere for 4 hours before
HUVECs were seeded on top at a density of 4  103/well. Cells were
cultured in EGM2, and the medium was changed every 2 days (50 g/mL
exosomes) for 10 days before fixation in methanol. Endothelial cells were
stained with anti-CD31 and goat anti–mouse antibodies (both from
Serotec). The vessels were then visualized with Sigma-Fast BCIP
(Sigma-Aldrich).
Proliferation assay
HUVEC proliferation was assessed with the CellTiter 96 AQueous One
Solution cell proliferation assay from Promega according to the manufactur-
er’s instructions.
Xenograft mouse models
All protocols were conducted with approval from the United Kingdom
Home Office and have been described previously.13 Exosomes (100 L at
50 g/mL) were mixed with U87 cells and Matrigel before injection with a
1-mL syringe and a 25-gauge needle. Exosomes (100 L at 50 g/mL)
were then injected into the edge of the growing tumor with a single injection
with a 1-mL syringe and a 27-gauge needle. This was performed 3 times
weekly for 5 weeks.
Immunohistochemistry and immunocytochemistry
The mouse CD31 staining protocol has been described previously.13 For
immunocytochemistry, cells were fixed in acetone and stained with
anti–human Dll4 (a gift from Regeneron) according to standard procedures.
Filopodia were stained with tetramethylrhodamine B isothiocyanate–
phalloidin (Sigma-Aldrich) according to the manufacturer’s procedures.
Results
Dll4 is incorporated into exosomes
HUVECs contain low levels of Dll4 under normal culture conditions.
They can be stimulated to produce Dll4 by plating the cells onto
Dll4-coated plates.14 This results in the activation of Notch signaling and
the transcription and production of Dll4, which can be inhibited by the
addition of the -secretase inhibitor dibenzazepine (Figure 1A). Under
these conditions, Dll4 can easily be detected in HUVEC lysates and in
the exosomes that the cells produce (Figure 1B). The Dll4 in the
exosomes appears to have the same molecular weight as the lysate,
which suggests that no substantial protein cleavage has occurred.
For subsequent experiments, a U87 cell line (which normally
does not express Dll4) was used that overexpresses human Dll4
(U87 Dll4). This allowed us to produce larger quantities of
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exosomes with and without Dll4. Western blotting confirmed that
Dll4 was present in the exosomes derived from the cell line that
overexpressed Dll4 (Figure 1C). Both sets of exosomes contained
known exosomal markers: LAMP1 (lysosomal-associated mem-
brane protein 1, a marker of late exosomes), TSG101 (tumor-
susceptibility gene 101, a member of the ESCRT [endosomal
sorting complex required for transport] machinery), and Rab5 (a
small GTPase involved in clathrin-mediated endocytosis).20
The level of exosome production was compared between the
cell lines (supplemental Table 2, available on the Blood Web site;
see the Supplemental Materials link at the top of the online article).
U87 control cells produce approximately 1.48 times more exo-
somes than U87 cells that overexpress Dll4. U87-Dll4 cells also
grow more slowly because of increased Notch signaling.13 Control
HUVECs produce 2.87 times more exosomes than HUVECs plated
onto Dll4. Activation of Notch signaling in these cells also reduces
their proliferation rate.2 Control U87 cells produce 8 times more
exosomes than control HUVECs. These data suggest that exosome
production is related to growth rate.
Characterization of the exosomes
Exosomes are observed to be between 40 and 100 nm in diameter
by electron microscopy.11 To assess particle size and size distribu-
tion, we used the NanoSight LM10 system for real-time visualiza-
tion and assessment of particles in solution. The modal sizes of the
U87 control exosomes and HUVEC exosomes were similar and
were estimated to be 120 and 114 nm, respectively (Figure 1D).
To further characterize the properties of our exosome preparations,
we performed an analysis by tandem mass spectrometry on exosomes
derived from U87 control cells. The analysis revealed 40 proteins, 95%
of which have been described previously as exosomal proteins (supple-
mental Table 1). These included extracellular matrix and cell-surface
proteins such as collagens, integrins, galectin, and CD44/63/151, as well
as intracellular components such as metabolic enzymes, G proteins, and
cytoskeletal components consistent with previous analyses.21 The remain-
ing proteins are other family members of previously known exosomal
proteins such as -enolase and may be more specific to U87-derived
exosomes. The high degree of correlation between the composition of
proteins identified and the previously known content of these particles
confirms the validity of the procedure we used to isolate exosomes from
these cells. Further analysis of control and Dll4-containing U87
exosomes by quantitative, comparative mass spectroscopy revealed an
additional 5 proteins that were only present in the Dll4-containing
exosomes, which have been described as having a role in angiogenesis
(supplemental Table 3) and have been reported to have roles in
endothelial cell migration, adhesion, proliferation, and vessel stabiliza-
tion.22 It is unclear whether their presence is a result of Notch signaling
or a direct interaction with the Dll4 itself, because a known Dll4-
interacting protein, DLG1, was also identified in the Dll4-containing
exosomes.23
Dll4-containing exosomes inhibit Notch signaling
To assess the effects of Dll4-containing exosomes on Notch
signaling, we measured the effects on downstream Notch targets
with a quantitative polymerase chain reaction protocol. As an
internal control, we activated Notch signaling by plating HUVECs
on Dll4-coated plates for 24 hours before RNA extraction (com-
pared with a bovine serum albumin control). This treatment
resulted in increased transcription of the Notch target genes Hey1
and Hey2 (Figure 2A). During plating on Dll4-coated plates, U87
exosomes (50 g/mL) were added to assess their effects. Control
exosomes had no significant effect on Notch signaling, but
Dll4-containing exosomes produced down-regulation of down-
stream Notch target expression (Figure 2A). HUVEC exosomes
isolated from cells plated on Dll4-coated plates were also capable
of inhibiting Notch signaling (Figure 2B). To confirm these results,
we investigated the production of NICD in response to Notch
activation by Western blotting. After a 24-hour incubation of
HUVECs on Dll4-coated plates, there was an accumulation of
NICD compared with the bovine serum albumin control (Figure
2C). This level was unaffected when HUVECs were plated onto
Dll4-coated plates in the presence of 50 g/mL control exosomes;
however, incubation with Dll4-containing exosomes resulted in an
inhibition of NICD accumulation (Figure 2C).
Notch signaling in HUVECs reduces cell proliferation2; there-
fore, the rate of proliferation was assessed in exosome-treated
HUVECs with an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide] assay. The addition of Dll4-containing
exosomes to HUVECs increased the rate of proliferation, which is
consistent with an inhibition of Notch signaling; however, control
exosomes were also capable of increasing proliferation (supplemen-
tal Figure 1). Tumor exosomes have been reported to induce
endothelial cell proliferation.24 Mass spectroscopy revealed that
U87 exosomes contained several proteins that are known to be
involved in proliferation (eg, G proteins), and their transfer to
Figure 1. Dll4 is incorporated into exosomes. (A) HUVECs were seeded onto
6-well plates at 3  105/well with or without the presence of 10nM dibenzazepine
(DBZ). The plates had been coated previously with either bovine serum albumin
(BSA; 1 g/mL) or recombinant hDll4 (1 g/mL) to induce Notch signaling. The cells
were lysed after 24 hours and subjected to Western blotting to detect Dll4 or -actin
as a loading control. (B) HUVECs were grown on recombinant hDll4–coated plates
for 48 hours in exosome-depleted EGM2. The medium was harvested, and the cells
were lysed in radioimmunoprecipitation assay buffer. The medium was ultracentri-
fuged to isolate the exosomes (exo), then the fractions were analyzed by Western
blotting to detect Dll4. (C) U87 Dll4 and U87 control cells were grown for 48 hours in
Opti-Mem before harvesting of the media and cell lysis. The exosomes were
harvested by ultracentrifugation and subjected to Western blotting to detect Dll4 and
exosomal markers. (D) Exosome size was analyzed with a NanoSight LM10; vertical
axis units 1  107 particles/mL per nanometer.
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HUVECs may contribute to their proliferative effects (supplemen-
tal Table 1).
Dll4-containing exosomes increase vessel branching and
vessel density in vitro
To investigate the function of Dll4-containing exosomes in angio-
genesis, HUVECs were mixed with fibroblasts to induce tube
formation in vitro. After plating of the cells, the medium was
changed to contain either 50 g/mL control exosomes or 50 g/mL
Dll4-containing exosomes. The medium was changed every 2 days,
with new exosomes added for a period of 10 days. The vessels were
stained with an anti-CD31 antibody, and the tube length, size,
density, and degree of branching were assessed with ImageJ
Version 1.41 software (National Institutes of Health). A typical
Figure 2. Dll4-containing exosomes inhibit Notch signaling. (A) HUVECs were plated onto bovine serum albumin (BSA)– or Dll4-coated 6-well plates at a density of
3  105/well in the presence of either control exosomes (50 g/mL) or Dll4-containing exosomes harvested from U87 (50 g/mL). After 24 hours, the cells were extracted in
TRI reagent to isolate the RNA. Quantitative polymerase chain reaction protocol was conducted to examine the Notch target genes Hey1 and Hey2. (B) Identical experiment
with exosomes isolated from HUVEC control cells or HUVECs plated on Dll4. Samples were analyzed in triplicate. One-way analysis of variance with a Tukey
multiple-comparison post hoc test was performed with GraphPad Prism 4.0b software. (C) The same experiment as shown in panel A, except after 24 hours, the cells were
lysed in radioimmunoprecipitation assay buffer and subjected to Western blotting to detect the level of NICD or -actin as a loading control. GAPDH indicates
glyceraldehyde-3-phosphate dehydrogenase; and exo, exosomes.
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example of tube formation after 10 days is shown in Figure 3B.
Statistical analysis revealed that there was a significant increase in
the number of nodes (branching) and number of tips formed when
the cells were incubated with Dll4-containing exosomes compared
with con-
trols. This also resulted in a significant increase in vessel density
(Figure 3A). This phenotype is consistent with an inhibition of
Notch signaling.25
Dll4-containing exosomes increase vessel branching, vessel
length, and vessel size in vivo
Control and Dll4-containing exosomes were injected into U87 xeno-
grafts 3 times per week for 5 weeks. At the end of the experiment,
the tumors were measured, and the Dll4-containing exosome–
treated tumors appeared to be slightly larger, although this was not
significant (supplemental Figure 2). The tumors were sectioned and
stained to visualize the vessels. Vessel density was high in all of the
tumors, and there was no significant difference in density between
the groups (supplemental Figure 2). There was, however, a
significant increase in vessel branching observed in the Dll4-
containing exosome–treated tumors compared with the controls,
which is consistent with an inhibition in Notch signaling (Figure
3C). There was also a significant increase in vessel length and size
in the Dll4-containing exosome–treated tumors (Figure 3C). Repre-
sentative images of vessels are shown in Figure 3D.
Dll4 can be transferred to another cell via exosomes
To determine the mechanism of Dll4-containing exosome–
mediated inhibition of Notch signaling, we looked at the subcellu-
lar location of the Dll4 after incubation with the exosomes.
U87GM cells, which contain no Dll4, were incubated for 24 hours
with 50 g/mL control or Dll4-containing exosomes and then
washed thoroughly with PBS before lysis in radioimmunoprecipita-
tion assay buffer. Western blotting revealed that the Dll4 from the
exosomes had been transferred to the U87GM cells (Figure 4A).
The association of Dll4-containing exosomes with the U87GM
cells was confirmed by immunocytochemistry (Figure 4B). To
resolve whether the exosomes were being internalized or were
strongly associated with the plasma membrane, U87 cells were
pelleted, after a 24-hour incubation with exosomes, then embedded
and sectioned to obtain slices through the cell. The sections were
then stained for human Dll4 (hDll4). Dll4 was only detected in the
cells incubated with Dll4-containing exosomes (50 g/mL), and it
appeared to be at the membrane and intracellular level (Figure 4C).
Figure 3. Dll4-containing exosomes increase vessel
branching. (A) Normal dermal fibroblasts were seeded
onto 24-well plates at a density of 2  104/well, and
HUVECs were seeded onto the fibroblasts at a density of
4  103/well. The cells were cultured for 10 days in
EGM2 with either control exosomes (50 g/mL) or Dll4-
containing exosomes (50 g/mL), with the media changed
every 2 days. Cells were fixed and stained as described
in “Methods,” and pictures were taken with a Zeiss
Axiovert 135 microscope at 5 magnification. (A) Three
batches of control exosomes and 3 batches of Dll4-
containing exosomes were tested, each in triplicate. Ten
images were captured from each well for analysis (a total
of 90 pictures for control and 90 for Dll4-containing
exosome–treated cells). (B) Representative images were
analyzed with ImageJ software for vessel length, size,
and density. The number of tips and nodes was also
counted. (C) U87 xenografts were grown and injected
3 times per week for 5 weeks with either PBS, control
exosomes (Control exo), or Dll4 exosomes (Dll4 exo,
isolated from U87 cells) at a concentration of 50 g/mL.
The animals were then killed and the tumors sectioned for
vessel staining. A Chalkley vessel count (CVC) was
performed for vessel density, and the vessel length and
lumen size were estimated with ImageJ. The number of
branches was counted manually and normalized to the
CVC. Data were analyzed by t test or 1-way analysis of
variance with a Tukey multiple-comparison post hoc test
with GraphPad Prism 4.0b software and shown as mean
with standard deviation. (D) Representative images taken
on a Nikon Eclipse E800 microscope at 10magnification.
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The exosomes were also labeled with the fluorescent membrane
dye PKH67 and incubated with HUVECs for 16 hours. The cells
were then analyzed by confocal microscopy to assess the position
of the exosomes, and they appeared to have been endocytosed
(Figure 5A). To assess cell-surface localization of the added Dll4,
cell-surface proteins were biotinylated and purified. A small
amount of Dll4 was present at the membrane in HUVECs under
normal culture conditions; however, after the addition of Dll4-
containing exosomes, the amount present at the membrane in-
creased substantially (Figure 5B). Incorporation of Dll4 into the
membrane was also apparent in U87GM cells after incubation with
Dll4-containing exosomes (Figure 5B).
Transfer of Dll4 occurs in vivo in tumor endothelium
Next, we addressed whether Dll4 can be transferred to mouse
endothelial cells in vivo using a tumor xenograft model. U87 cells
that overexpressed Dll4 or control U87 cells were implanted
subcutaneously into BALB/c severe combined immunodeficiency
(SCID) mice. The tumors were grown until they reached maximum
size, at which time the mice were killed and the tumors harvested
for immunohistochemistry. The tumor sections were stained with
an antibody specific for hDll4, confirmation of which is shown in
supplemental Figure 3A-B. We further confirmed that we were
unable to detect mouse Dll4 in control tumor vessels (Figure 6A);
however, hDll4 was easily detectable in tumors derived from U87
Dll4 cells and was detectable in the mouse vessels (Figure 6A). To
confirm that this phenomenon was a result of ligand transfer and
not vascular mimicry by the tumor cells, we stained serial sections
of vessels with anti-hDll4 and anti–mouse CD31 antibodies. The
cells surrounding the vessel were positive for both mouse CD31
and hDll4, which confirms that the mouse endothelial cells had
acquired the hDll4 (Figure 6B). Higher-magnification images
revealed that the transferred hDll4 was found intracellularly and at
the membrane in the vessels. Surprisingly, there was also specific
staining of hDll4 on the mouse red blood cells (RBCs; supplemen-
tal Figure 3C), which suggests that the hDll4 can transfer to the
trapped RBCs. RBCs in control tumors were completely negative
for this staining (supplemental Figure 3D).
Dll4-containing exosomes reduce the level of Notch receptors
at the cell surface
It is clear that Dll4 is transferred to target cells, and it can be
incorporated into the plasma membrane; however, it is unclear how
this transfer inhibits Notch signaling. One possibility is that Dll4 on
the exosomes binds to the Notch receptor and targets it for
internalization with the rest of the exosomes. To explore this
hypothesis, the membrane proteins were biotinylated and purified
after incubation with exosomes. The level of Notch1 extracellular
domain was assessed by Western blotting. Notch1 receptor was
present at the membrane in HUVECs incubated with control
exosomes; however, the level was almost completely ablated by the
Figure 4. Dll4 is transferred to other cells via exosomes. (A) U87GM cells were
seeded onto 6-well plates at 3  105/well. The cells were then incubated with either
control exosomes (50 g/mL) or Dll4-containing exosomes (50 g/mL) in Opti-Mem
for 24 hours before extensive washing with PBS and lysis in radioimmunoprecipita-
tion assay buffer. Lysates were subjected to Western blotting and were probed with
either anti-Dll4 or -tubulin as a loading control. Exo indicates exosomes. (B) The
same experiment was repeated, except the cells were fixed in acetone after the
24-hour incubation. They were then stained with anti-hDll4. Images were taken on a
Nikon Eclipse E800 microscope at 40 magnification. (C) U87 cells incubated with
exosomes (50 g/mL) for 24 hours were pelleted, embedded, and sectioned. The
sections were then stained with anti-hDll4, and images were taken at 50magnifica-
tion with a Nikon Eclipse E800 microscope.
Figure 5. Dll4-containing exosomes transfer Dll4 to the membrane, reduce
Notch1 receptor levels, and are endocytosed. (A) Dll4-containing exosomes were
labeled with a red fluorescent dye (PKH67) as described in “Methods.” HUVECs were
incubated with Dll4-containing exosomes (50 g/mL) for 16 hours before images
were acquired with a Zeiss LSM 510 confocal microscope at 63 magnification.
Images shown are a midsection slice through the cells showing intracellular
localization of the exosomes and exclusion from the nucleus. Phase-contrast image
and merged image show that fluorescence did not occur at the membrane.
(B) HUVECs or U87GM cells were seeded at a density of 3  106 cells/150 cm2 dish.
Each dish was incubated for 24 hours with control exosomes (50 g/mL) or
Dll4-containing exosomes (50 g/mL) before the cell-surface proteins were biotinyl-
ated and purified as described in “Methods.” The purified proteins were subjected to
Western blotting to detect Dll4 or Notch 1 at the cell membrane, with CD31 probed as
a loading control. (C) The same experiment was repeated, except the cells were
lysed to isolate total protein. The lysates were subjected to Western blotting to detect
total Notch1, with -actin used as a loading control. Exo indicates exosomes.
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presence of Dll4-containing exosomes (Figure 5B). Total cellular
Notch1 was also reduced in cell lysates after incubation with
Dll4-containing exosomes, which suggests that Notch receptor is
internalized and degraded rather than internalized and recycled to
the surface at a later time point (Figure 5C).
Dll4-containing exosomes can reduce the level of stalk cell
markers and induce a tip cell phenotype
The default phenotype of endothelial cells is a tip cell, whereas
activation of Notch signaling confers a stalk cell phenotype. We
and others have demonstrated previously that activation of
Notch signaling in endothelial cells using recombinant Dll4-
coated plates results in the up-regulation of the stalk cell
markers Jagged-1 and vascular endothelial growth factor recep-
tor-1.2,14 To assess whether Dll4-containing exosomes are
capable of reversing the expression of stalk cell markers,
endothelial cells were incubated with 50 g/mL of Dll4-
containing exosomes or control exosomes for 24 hours in the
presence of recombinant Dll4. Control exosomes had no effect
on Jagged-1 and vascular endothelial growth factor receptor-1
expression; however, Dll4-containing exosomes inhibited their
expression (Figure 7A). The presence of filopodia is a tip cell
hallmark.2 To assess the effects of Dll4-containing exosomes on
filopodia formation, HUVECs were incubated for 24 hours in
the presence of 3 different batches of 50 g/mL of control or
Dll4-containing exosomes before being stained with tetrameth-
ylrhodamine B isothiocyanate–phalloidin. The filopodia were
counted, and their number was found to be significantly higher
on the Dll4-containing exosome–treated cells. Interestingly, the
filopodia were also significantly longer (Figure 7B-C). These
data also suggest that the Dll4-containing exosomes can confer a
tip cell phenotype.
Discussion
It has been speculated that Dll4 is incorporated into exosomes.8
This stems from several studies that have identified endocytosis of
DLLs as a key step during Notch signaling in Drosophila. We
demonstrated that upon induction of Dll4 in HUVECs, the protein
is indeed incorporated into exosomes. This also occurs in the U87
overexpression model. The exosomes have a proteomic profile that
matches published data and are only slightly larger than the
suggested size of exosomes (modal size of 114 nm for HUVECs
and 120 nm for U87 cells, compared with published sizes of
50-100 nm). Exosome size is normally estimated with electron
microscopy, which has its limitations. With that technique, exo-
somes are fixed and dehydrated, which may result in shrinkage and
hence an underestimation of their actual size. Furthermore, the
analysis of images of exosomes obtained by electron microscopy is
highly subjective. Nanoparticle tracking analysis (NanoSight Ltd)
overcomes these issues, because exosomes can be measured in a
biologic buffer such as PBS, thus eliminating any shrinkage of the
particles. Moreover, nanoparticle tracking analysis is an objective
technique in which large numbers of individual particles are
tracked, sized, and displayed in the analysis profile. It has also been
shown by atomic force microscopy that light-scattering techniques
are superior to electron microscopy in determining the size of
particles in solution.26We therefore conclude that we obtained
good-quality exosome preparations.
We have demonstrated that Dll4 can be transferred from
exosomes to cells after coincubation. Dll4 was internalized with the
exosomes as visualized by immunocytochemistry, and the protein
was found to be located intracellularly and at the cell membrane by
both immunohistochemistry and biotin labeling. Cellular uptake of
exosomes requires clathrin-mediated endocytosis, which has been
reported to result in the transfer of cytosol and membrane from the
exosome to the cell in the proper topology.27 This type of transfer
has been reported previously with an oncogenic mutant form of
epidermal growth factor receptor (EGFRvIII), which is incorpo-
rated into microvesicles of cultured U373 glioma cells that
overexpress the EGFRvIII mutant. These vesicles can fuse with
cells that lack the mutant receptor and confer a transformed
phenotype.28 However, the glioblastoma cell line used in the
present study does not express the mutant EGFR, and we isolated
exosomes, not microvesicles, which may contain larger plasma
membrane–derived particles.
We also demonstrated the transfer of Dll4 in vivo. We postulate
that this transfer occurs via exosomes. Exosomes have been shown
to interact with target cells to regulate cell-cell communication.
This has been demonstrated in the immune system, where dendritic
cells release exosomes that contain major histocompatibility com-
plex to stimulate T-cell activation.18 Glioblastoma and ovarian
tumor cells have also been shown to release exosomes that are
capable of stimulating tube formation in vitro.29,30 These studies
used microvesicles, which contain larger plasma membrane–
derived particles, which may be responsible for the enhanced tube
formation. We reported Dll4 expression in colon cancer tumor
cells, so there is a potential for human cancers to give rise to
Dll4-containing exosomes.31 A surprising finding was hDll4 stain-
ing on mouse RBCs in the U87 Dll4 tumors but not the controls.
This will need further study, (eg, isolation of mouse RBC
membranes) but does suggest that other cell types may take up
exosomes.
Figure 6. Dll4 can be transferred to mouse endothelial cells in vivo. (A) Immuno-
histochemical staining of hDll4 in control tumors derived from U87 cells or tumors
derived from U87 overexpressing Dll4. hDll4 staining was not detectable in mouse
tissue (red arrow); however, hDll4 staining was detectable in tumor tissue (white
arrow) and in mouse vessels (yellow arrow). (B) Immunohistochemical staining of
serial sections derived from a U87 Dll4 tumor to detect mouse CD31 and human Dll4.
The cells surrounding the vessel were positive for CD31 and hDll4, which confirms
that the mouse endothelial cells had acquired the hDll4 from the tumor cells. Images
were taken with a Nikon Eclipse E800 microscope at 40magnification.
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We have demonstrated that Dll4-containing exosomes are also
capable of effecting tube formation, increasing branching and
overall vessel density, in an in vitro tube assay. An increase in
vessel branching was also observed in vivo after injection of
Dll4-containing exosomes into tumor xenografts. This is indicative
of Notch inhibition, because enhanced tip cell formation and
endothelial sprouting have been shown to occur when other
inhibitors of Notch signaling are used, such as soluble Dll4-Fc,
anti-Dll4 antibodies, or -secretase inhibitors.32,33 An increase in
vessel length and lumen size was also observed in the present in
vivo model. This phenotype has been described previously in our
laboratory when Dll4 was overexpressed in the U87 model13;
however, the vessel density was reduced because of Dll4 over-
expression and increased Notch signaling.
We demonstrated that the Dll4-containing exosomes inhibited
Notch signaling upon their uptake into endothelial cells, which
could be responsible for the increased branching seen in vivo;
however, we speculate that their eventual role is to promote a tip
cell phenotype. During normal angiogenesis, a tip cell will promote
the growth of new vessels and activate Notch signaling in
Figure 7. Dll4-containing exosomes reduce the level of stalk cell markers and confer a tip cell phenotype. (A) HUVECs were plated onto bovine serum albumin (BSA) or
Dll4-coated 6-well plates at a density of 3  105/well in the presence of either control exosomes (50 g/mL) or Dll4-containing exosomes (50 g/mL). After 24 hours, the cells
were extracted in TRI reagent to isolate the RNA. Quantitative polymerase chain reaction protocol was performed to examine the stalk cell markers Jagged-1 and vascular
endothelial growth factor receptor-1 (VEGFR1). Samples were analyzed in triplicate. One-way analysis of variance with a Tukey multiple-comparison post hoc test was
performed with GraphPad Prism 4.0b software. Exo indicates exosomes. (B) HUVECs were incubated with 3 different batches of control or Dll4-containing exosomes for
24 hours before staining with tetramethylrhodamine B isothiocyanate–phalloidin to visualize the filopodia. (C) The filopodia were counted on 40 cells from each condition, and
the length of the longest 3 filopodia on each cell was assessed with ImageJ. Images were taken on a Zeiss Axioskop 2 microscope at 63magnification. Data were analyzed by
t test with GraphPad Prism 4.0b software and are shown as mean with SD.
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neighboring cells, which may explain why the Dll4-containing
exosomes also have the ability to form longer, larger vessels. Other
angiogenic proteins have also been identified in the Dll4 exosomes
and may contribute to these effects on tube formation; however,
these proteins have not been reported to enhance branching and tip
formation.
There are several potential mechanisms that may be involved in
switching HUVECs to a tip cell phenotype. First, the Dll4-
containing exosomes can reduce Notch signaling and reduce the
expression of stalk cell markers. Dll4-containing exosomes may
bind to the Notch receptor at the cell surface and compete with
membrane-bound ligands. Soluble ligands have been reported to
act in a similar manner and to block signaling induced by Notch
trans ligands.6 However, we have strikingly demonstrated that
Dll4-containing exosomes remove the Notch1 receptor from the
cell surface. Because our confocal microscopy experiments demon-
strated that the exosomes were internalized, this suggests that the
Dll4 on the exosomes binds to the receptor at the cell surface and
internalizes it with the rest of the exosome. The Notch receptor is
ultimately degraded, as demonstrated by a total loss of cellular
receptor. It may also be “trapping” newly synthesized Notch
receptor in endosomal compartments before it reaches the cell
surface, because intracellular interaction of Delta and Notch has
been reported to reduce the ability of Notch to interact with Delta
on neighboring cells.34
The concentration of Dll4 in the cell membrane may also be
responsible in part for the inhibition of Notch signaling. Altering
the ratio of DLL to Notch receptor has been shown to change the
cell signaling response. Overexpression of DLL in Drosophila
inhibits Notch signaling by making the signal-receiving cell
refractory to the signal; conversely, reducing the level of DLL in
the receiving cell makes the cell more receptive.35 DLLs are
capable of inhibiting Notch signaling through interaction with
Notch in the same cell.34 This cis-interaction may stimulate
Notch endocytosis or stop Notch from reaching the cell surface;
however, cell-surface expression of ligand has also been shown
to be required for cis-inhibition.36,37 Notch-ligand interactions
within the same cell may compete with trans-ligand interactions,
because cells that overexpress Notch1 and Dll1 are unable to
bind ligands on another cell.34 Increases of ligand at the cell
surface may also promote ligand-ligand interactions and de-
crease available ligand for trans-activation of Notch, although
ligand-ligand interactions are weaker than Notch-ligand interac-
tions.38-40 None of these effects would be expected to produce
the marked depletion of cell-surface Notch. The presence of
Dll4 on the cell surface with low Notch signaling, however, is
another tip cell–like phenotype.
If endothelial cells secrete exosomes that contain Dll4 in
vivo, how could this affect surrounding cells? Dll4 is expressed
on tip cells, and it controls tip/stalk cell differentiation and
inhibits the angiogenic response of adjacent endothelial cells to
vascular endothelial growth factor stimulation through Notch
signaling.32 Dll4 on the tip cell activates Notch on an adjacent
endothelial cell, which commits the cell to a stalk cell pheno-
type. Notch signaling in the stalk cell then up-regulates the
expression of Dll4, which can activate Notch on the next cell,
hence producing a line of Notch-signaling stalk cells. Evidence
for this was described in the developmental retinal angiogenesis
model reported by Hellstrom et al.41 In this system, Dll4 was
expressed and seen to accumulate intracellularly in the tip cells
and in many of the stalk cells immediately in contact with the tip
cells. Further away from the tip, the intracellular Dll4 signal
decreased. This intracellular accumulation of DLLs has been
described previously and is thought to correlate well with Notch
signaling7,42; however, this accumulation could also be an
indication of exosome formation. Dll4-containing exosomes
produced by these cells could diffuse and be taken up by
endothelial cells in their immediate vicinity. We have demon-
strated that uptake of Dll4-containing exosomes by endothelial
cells results in the cells having a higher Dll4/Notch-receptor
ratio and a lower Notch-signaling capacity. Dll4-containing
exosomes are also capable of reducing the expression of the
stalk cell markers Jagged-1 and vascular endothelial growth
factor receptor-12 and increasing the level of filopodia. The
exosomes, therefore, appear to be able to confer a tip cell
phenotype on the receiving cells and may represent a mecha-
nism by which stalk cell differentiation is restricted to allow tip
cell formation to reoccur to produce an even network of vessels.
In summary, we present evidence that Dll4 is incorporated into
the exosomes of endothelial cells and tumor cells. Dll4 can be
transferred from one cell type to another by exosomes in vitro and
in vivo. D114-containing exosomes increase angiogenesis by
inhibition of Notch signaling and consequently confer a tip cell
phenotype on endothelial cells. Thus, our results suggest a new
mechanism of DLL/Notch signal regulation that does not require
classic cell-cell contact.
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